Gyre Therapeutics
Gyre Therapeutics' revenue rose 10.2% to $117 million in fiscal 2025. Its operating margin was 9.8%, down from 15.3% a year earlier. Free cash flow was −$0 million. The diluted share count rose 0.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Gyre Therapeutics does
Gyre Therapeutics is a drug company that sells medicines in China and develops new ones for fibrosis, the scarring and stiffening of organs such as the lungs and liver, and for inflammatory diseases. It works mainly through Gyre Pharmaceuticals, a Beijing company it owns most of, and has a small U.S. operation based in San Diego.
It makes its money mainly from selling medicines in China, through a network of distributors. Its main product is ETUARY (pirfenidone), a treatment for idiopathic pulmonary fibrosis, a lung-scarring disease, which had sales of $106.1 million in 2025. It also sells Etorel (nintedanib), another lung fibrosis drug launched in June 2025, Contiva (avatrombopag), a blood-platelet drug launched in March 2025, and some generic drugs. Its five largest customers account for a large part of its revenue.
Its lead drug in development is Hydronidone, for liver fibrosis caused by chronic hepatitis B in China and by fatty liver disease in the United States; it met its main goal in a late-stage trial in China in 2025. At the end of 2025 Gyre had a sales and marketing team of 405 people in China and seven full-time employees in the United States. In March 2026 it agreed to merge with Cullgen, a privately held drug developer; the deal still had to be completed.
Its biggest risks, as it describes them
- Heavy dependence on sales of ETUARY in China, where it faces competition.
- Pressure from Chinese government price cuts, bulk-buying programs and hospital tenders on its drugs.
- Its drugs being dropped from China's national list of medicines that insurance pays for.
- Hydronidone and other drugs in development failing in trials or being delayed.
- The merger with Cullgen may be delayed, not be completed, or not bring the benefits it expects.
Income statement
From fiscal 2022 to 2025, earnings per share fell 12.6% a year and net income grew 32.0% a year, as new shares raised the share count by 36% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 47 | 22 | 34 | 27 | 52 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −47 | −22 | −34 | −27 | −52 |
| Net debt to EBITDA | — | −2.1x | — | −1.5x | −3.8x |
| Debt to equity | 0.0x | 0.0x | — | 0.0x | 0.0x |
| Interest coverage | — | — | — | — | — |
| Current ratio | 3.6x | 4.1x | 2.9x | 3.3x | 5.6x |
| Quick ratio | 3.6x | 3.6x | 2.6x | 3.0x | 5.4x |
Cash flow
Projections
Project Gyre Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Gyre Therapeutics says to expect
- Full year 2026: revenue
Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Gyre Therapeutics shares on the open market, and 2 insiders sold $952,874, $82,927 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | Weiguo YeChief Operating Officer | Sold | 3,000 | $6.35 | $19,050 | Form 4 |
| Jun 11, 2026 | Weiguo YeChief Operating Officer | Sold | 2,800 | $6.17 | $17,276 | Form 4 |
| Jun 10, 2026 | Weiguo YeChief Operating Officer | Sold | 6,418 | $6.21 | $39,856 | Form 4 |
| Jun 10, 2026 | Weiguo YeChief Operating Officer | Sold | 5,000 | $6.24 | $31,200 | Form 4 |
| Jun 9, 2026 | Weiguo YeChief Operating Officer | Sold | 14,500 | $6.14 | $89,030 | Form 4 |
| Jun 9, 2026 | Weiguo YeChief Operating Officer | Sold | 3,000 | $6.15 | $18,450 | Form 4 |
| Jun 5, 2026 | Weiguo YeChief Operating Officer | Sold | 15,401 | $6.40 | $98,566 | Form 4 |
| Jun 4, 2026 | Weiguo YeChief Operating Officer | Sold | 19,575 | $6.13 | $119,995 | Form 4 |
| May 26, 2026 | Weiguo YeChief Operating Officer | Sold | 4,000 | $6.10 | $24,400 | Form 4 |
| May 22, 2026 | Weiguo YeChief Operating Officer | Sold | 3,500 | $6.08 | $21,280 | Form 4 |
| May 21, 2026 | Weiguo YeChief Operating Officer | Sold | 12,820 | $6.15 | $78,843 | Form 4 |
| May 20, 2026 | Weiguo YeChief Operating Officer | Sold | 9,400 | $6.15 | $57,810 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 4 of 9 | 4 of 9 |
| Rule of 40 | 26.2% | −12.4% | 10.1% |
| Altman Z'' | −3.79 | 5.15 | 8.71 |
| Accruals ratio | −110.7% | 17.8% | 6.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Pass | Fail | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 4 of 9 | 4 of 9 | 4 of 9 |
Compare
Put Gyre Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Gyre Therapeutics | FY25 | 10.2% | 9.8% | −0.1% | 9.7% | −3.8x | 4 | |
| Zhengye Biotechnology | FY25 | −37.6% | −60.6% | 10.6% | −14.9% | — | 3 | Compare |
| UroGen Pharma | FY25 | 21.4% | −113.7% | −148.2% | — | — | 2 | Compare |
| Zevra Therapeutics | FY25 | 350.9% | −59.1% | −2.3% | −218.8% | — | 5 | Compare |
| Zymeworks | FY25 | 38.9% | −87.3% | −32.6% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | 1 | 0 | — | 21 | 7 | 102 | 113 | 106 | 117 |
| Revenue growth | — | — | −99.4% | — | — | −65.0% | 1,294.0% | 10.9% | −6.8% | 10.2% |
| Gross profit | — | — | — | — | — | — | 98 | 109 | 102 | 111 |
| Research and development | 12 | 13 | 22 | 44 | 53 | 69 | 17 | 14 | 12 | 14 |
| Operating income | −20 | −22 | −34 | −57 | −57 | −88 | 9 | −67 | 16 | 12 |
| Net income | −17 | −22 | −30 | −55 | −56 | −88 | 4 | −86 | 18 | 10 |
| Diluted EPS (US$) | −21.75 | −7.45 | −2.68 | −4.60 | −2.93 | −2.87 | 0.03 | −1.41 | 0.05 | 0.02 |
| Diluted shares (millions) | 1 | 3 | 11 | 12 | 19 | 31 | 76 | 66 | 102 | 103 |
| Cash flow | ||||||||||
| Cash from operations | −18 | −20 | −29 | −44 | −55 | −84 | 11 | 26 | −4 | 1 |
| Capital expenditure | 0 | 0 | 0 | 0 | — | 1 | 5 | 8 | 2 | 1 |
| Free cash flow | −19 | −20 | −29 | −44 | — | −85 | 6 | 17 | −6 | −0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 45 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 3 | 3 | 4 | 3 | 13 | 7 | 1 | 7 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 17 | 32 | 120 | 77 | 82 | 47 | 22 | 34 | 27 | 52 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 38 | 40 | 125 | 99 | 95 | 56 | 85 | 116 | 125 | 166 |
| Total liabilities | 22 | 9 | 5 | 30 | 19 | 15 | 12 | 38 | 27 | 24 |
| Shareholders' equity | 16 | 31 | 120 | 68 | 76 | 41 | 42 | −16 | 63 | 106 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | 95.3% | 95.9% | 96.3% | 95.3% |
| Operating margin | — | −2,143.6% | −563,700.0% | — | −273.9% | −1,197.8% | 9.0% | −59.3% | 15.3% | 9.8% |
| Net margin | — | −2,118.0% | −500,916.7% | — | −268.5% | −1,198.3% | 4.2% | −75.3% | 16.9% | 8.5% |
| Free cash flow margin | — | −1,961.0% | −482,150.0% | — | — | −1,152.8% | 5.6% | 15.3% | −5.6% | −0.1% |
| Rule of 40 (growth + FCF margin) | — | — | −482,249.4% | — | — | −1,217.8% | 1,299.5% | 26.2% | −12.4% | 10.1% |
| Return on capital | — | — | — | — | — | — | 14.6% | −343.0% | 47.8% | 9.7% |
| Return on equity | −71.3% | −92.0% | −39.9% | −58.6% | −77.9% | −150.1% | 10.3% | −640.4% | 75.4% | 11.7% |
| Return on assets | −31.5% | −55.6% | −36.6% | −49.4% | −58.2% | −116.8% | 6.1% | −84.9% | 14.8% | 6.8% |
| Net debt to EBITDA | — | — | — | — | — | — | −2.1x | — | −1.5x | −3.8x |